At the same time, the research into IPF and other fibrotic diseases could also shed light on the long-term effects of COVID-19. Although the fibrosis that occurs through COVID may have a different ...

Overall, the collective findings from this Phase 1b clinical trial provide the Company with strong confidence that LTI-03 has ...

IPF severely impacts quality of life, limiting daily activities due to progressive respiratory decline. Median survival for IPF patients is approximately 3 to 5 years post-diagnosis. The financial ...

There's been widespread interest in hydroxychloroquine as both a preventative measure and for treating patients with coronavirus. President Trump has used it as a preventative measure, and ...

With the acute phase of the Covid-19 pandemic fading even as the coronavirus persists and evolves, a new normal is taking shape around the world. Experts worry the unusual move, driven by vaccine ...

Comorbidities can obscure IPF symptoms, leading to diagnostic delays or misdiagnoses, complicating the clinical presentation. Comprehensive evaluation is crucial to tailor treatment plans ...

Tissue-engineering techniques are in the works to regrow heart muscle after a heart attack and repair lungs and other organs.

COVID’s Risk to Heart May Rival That of Heart DiseaseHaving severe COVID-19 could mean a higher risk of heart attack and stroke for up to three years after infection, new research shows.

They may be proverbial ‘lab rats’ but patients who participate in clinical trials are doing more than just undergoing tests – ...

Rashes and other skin changes may be a sign of COVID-19, in addition to classic symptoms like a cough, fatigue, fever, and sore throat. Some people develop a COVID rash, which can appear on body ...

BEACON-IPF Phase 2b trial on track for full enrollment in the first ... the impact of current macroeconomic and marketplace conditions, including the effects of COVID-19, on our business, operations, ...